Cargando…
A Decade of Data Protection for Innovative Drugs in Canada: Issues, Limitations, and Time for a Reassessment
Drug regulators in Canada and in other nations require innovative pharmaceutical companies to submit undisclosed clinical or other data as a condition of approving the marketing of new pharmaceutical products—the origination of which involves considerable effort and investment. Data protection regul...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Mary Ann Liebert, Inc.
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5178005/ https://www.ncbi.nlm.nih.gov/pubmed/28077911 http://dx.doi.org/10.1089/blr.2016.29030.mk |